6-(bromomethyl)pyridine-2-carboxylate | 885951-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(bromomethyl)pyridine-2-carboxylate
• 英文别名: 6-(Bromomethyl)picolinic acid；6-(bromomethyl)pyridine-2-carboxylic acid
• CAS: 885951-67-7
• 化学式: C₇H₆BrNO₂
• 分子量: 216.034
• InChiKey: YLHLANHPBJQXGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(bromomethyl)pyridine-2-carboxylate 在 盐酸 作用下， 以 水 为溶剂， 反应 75.0h， 生成 6-(phosphonomethyl)pyridine-2-carboxylate
  参考文献：
  名称：

  Garuti; Ferranti; Ronerti, Pharmazie, 1992, vol. 47, # 4, p. 295 - 297

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 3.0h， 生成 6-(bromomethyl)pyridine-2-carboxylate
  参考文献：
  名称：

  Garuti; Ferranti; Ronerti, Pharmazie, 1992, vol. 47, # 4, p. 295 - 297

  摘要：

  DOI：

文献信息

• [EN] AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE<br/>[FR] ALDÉHYDES AROMATIQUES AYANT UNE ACTIVITÉ PHARMACOLOGIQUE SOUTENUE ET AMÉLIORÉE IN VITRO ET IN VIVO POUR TRAITER LA DRÉPANOCYTOSE
  申请人：UNIV VIRGINIA COMMONWEALTH

  公开号：WO2019182938A1

  公开（公告）日：2019-09-26

  Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).

  提供了一种通过给予至少一种化合物来预防和/或治疗镰状细胞病（SCD）的一个或多个症状的化合物和方法。这些化合物基于香草醛，经过化学改性以增加生物利用度和活性，例如使这些化合物与血红蛋白（Hb）的F螺旋结合，从而防止红细胞（RBCs）的粘附。
• Novel tricyclic derivatives and their use
  申请人：Chang Dong Jo

  公开号：US20070021427A1

  公开（公告）日：2007-01-25

  The present invention relates to tricyclic colchicine derivatives represented by the formulas (I) or (II), pharmaceutically acceptable salts thereof, and a method for providing an immuno-suppressive or immuno-modulating effect, an anti-proliferative effect, an anti-inflammatory effect or a method for treating cancer comprising administering to a patient an effective amount of one or more colchicine derivatives:

  本发明涉及三环秋水仙素衍生物，其公式表示为(I)或(II)，以及其药学上可接受的盐，以及提供免疫抑制或免疫调节作用、抗增殖作用、抗炎作用或治疗癌症的方法，包括向患者施用一种或多种秋水仙素衍生物的有效量。
• BIFUNCTIONAL CHELATING AGENTS
  申请人：ADAM Mike

  公开号：US20110313130A1

  公开（公告）日：2011-12-22

  A bifunctional chelating agent of the formula (I): wherein the variables R 1 , R 1′ , Q 1 , Q 2 and M are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a stable or radioactive metal; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate.

  一种具有以下式子（I）的双功能螯合剂： 其中变量R1、R1'、Q1、Q2和M如本申请说明书所定义。本文还描述了上述螯合剂与稳定或放射性金属离子形成的配合物；与生物载体共价结合的复合物；以及含有该复合物的制药组合物。
• Second Generation Tetrahydroquinoline-Based Protein Farnesyltransferase Inhibitors as Antimalarials
  作者：Pravin Bendale、Srinivas Olepu、Praveen Kumar Suryadevara、Vivek Bulbule、Kasey Rivas、Laxman Nallan、Brian Smart、Kohei Yokoyama、Sudha Ankala、Prakash Rao Pendyala、David Floyd、Louis J. Lombardo、David K. Williams、Frederick S. Buckner、Debopam Chakrabarti、Christophe L. M. J. Verlinde、Wesley C. Van Voorhis、Michael H. Gelb

  DOI：10.1021/jm0703340

  日期：2007.9.1

  Substituted tetrahydroquinolines (THQs) have been previously identified as inhibitors of mammalian protein farnesyltransferase (PFT). Previously we showed that blocking PFT in the malaria parasite led to cell death and that THQ-based inhibitors are the most potent among several structural classes of PFT inhibitors (PFTIs). We have prepared 266 THQ-based PFTIs and discovered several compounds that inhibit the malarial enzyme in the sub- to low-nanomolar range and that block the growth of the parasite (P. falciparum) in the lownanomolar ran-e. This body of structure- activity data can be rationalized in most cases by consideration of the X-ray structure of one of the THQs bound to mammalian PFT together with a homology structural model of the malarial enzyme. The results of this study provide the basis for selection of antimalarial PFTIs for further evaluation in preclinical drug discovery assays.
• CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0672059A1

  公开（公告）日：1995-09-20